Simvastatin alleviates cardiac fibrosis induced by infarction via up-regulation of TGF-β receptor III expression

British Journal of Pharmacology

Volumn 172, Issue 15, 2015, Pages 3779-3792

  Sun, Fei ^a   Duan, Wenqi ^a   Zhang, Yu ^a   Zhang, Lingling ^a   Qile, Muge ^a   Liu, Zengyan ^a   Qiu, Fang ^a   Zhao, Dan ^a   Lu, Yanjie ^a   Chu, Wenfeng ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

JANUS KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE P38; RECEPTOR INTERACTING PROTEIN SERINE THREONINE KINASE; SCAFFOLD PROTEIN; SHORT HAIRPIN RNA; SIMVASTATIN; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 3; GIPC PROTEIN, MOUSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PROTEOGLYCAN; SIGNAL TRANSDUCING ADAPTOR PROTEIN; TRANSFORMING GROWTH FACTOR BETA RECEPTOR;

ANIMAL CELL; ANIMAL MODEL; ARTERIAL WALL THICKNESS; ARTICLE; CARBOXY TERMINAL SEQUENCE; CELL CULTURE; CELL ISOLATION; CELL PROLIFERATION; CELL VIABILITY; COLLAGEN FIBER; COLLAGEN SYNTHESIS; CONTROLLED STUDY; ECHOCARDIOGRAPHY; ELECTRON MICROSCOPY; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; HEART CONTRACTION; HEART DISEASE; HEART FUNCTION; HEART INFARCTION; HEART LEFT VENTRICLE ENDSYSTOLIC VOLUME; HEART MUSCLE FIBROSIS; IMMUNOPRECIPITATION; IN VIVO STUDY; LEFT ANTERIOR DESCENDING CORONARY ARTERY; LENTIVIRINAE; MALE; MOUSE; NEWBORN; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; RISK FACTOR; SIGNAL TRANSDUCTION; SYSTOLE; TRANSMISSION ELECTRON MICROSCOPY; UPREGULATION; VASCULAR REMODELING; ANIMAL; BIOSYNTHESIS; CELL SURVIVAL; DRUG EFFECTS; FIBROSIS; GENE SILENCING; GENETICS; METABOLISM; MYOCARDIAL INFARCTION; PATHOLOGY;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; CELL SURVIVAL; CELLS, CULTURED; ECHOCARDIOGRAPHY; FIBROSIS; GENE KNOCKDOWN TECHNIQUES; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MAP KINASE SIGNALING SYSTEM; MICE; MYOCARDIAL INFARCTION; PROTEOGLYCANS; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; SIMVASTATIN; UP-REGULATION;

EID: 84937019991     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.13166     Document Type: Article

References (49)

1. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al. (2013a). The Concise Guide to PHARMACOLOGY 2013/14: Catalytic Receptors. Br J Pharmacol 170: 1676-1705.
2. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al. (2013b). The Concise Guide to PHARMACOLOGY 2013/14: Enzymes. Br J Pharmacol 170: 1797-1867.
3. Askevold ET, Nymo S, Ueland T, Gravning J, Wergeland R, Kjekshus J, et al. (2013). Soluble glycoprotein 130 predicts fatal outcomes in chronic heart failure: analysis from the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA). Circ Heart Fail 6: 91-98.
4. Backlund T, Palojoki E, Saraste A, Eriksson A, Finckenberg P, Kyto V, et al. (2004). Sustained cardiomyocyte apoptosis and left ventricular remodelling after myocardial infarction in experimental diabetes. Diabetologia 47: 325-330.
5. Blobe GC, Liu X, Fang SJ, How T, Lodish HF, (2001). A novel mechanism for regulating transforming growth factor beta (TGF-beta) signaling. Functional modulation of type III TGF-beta receptor expression through interaction with the PDZ domain protein, GIPC. J Biol Chem 276: 39608-39617.
6. Chen J, Bi H, Hou J, Zhang X, Zhang C, Yue L, et al. (2013). Atorvastatin overcomes gefitinib resistance in KRAS mutant human non-small cell lung carcinoma cells. Cell Death Dis 4: e814.
7. Chu W, Li X, Li C, Wan L, Shi H, Song X, et al. (2011). TGFBR3, a potential negative regulator of TGF-beta signaling, protects cardiac fibroblasts from hypoxia-induced apoptosis. J Cell Physiol 226: 2586-2594.
8. Cleland JG, McMurray JJ, Kjekshus J, Cornel JH, Dunselman P, Fonseca C, et al. (2009). Plasma concentration of amino-terminal pro-brain natriuretic peptide in chronic heart failure: prediction of cardiovascular events and interaction with the effects of rosuvastatin: a report from CORONA (Controlled Rosuvastatin Multinational Trial in Heart Failure). J Am Coll Cardiol 54: 1850-1859.
9. Desai P, Jay A, Bock C, Dyson G, Okwuosa T, Simon MS, (2013). Evaluation of the effect of genetic variation on the relationship between statins, cardiovascular disease and cancer. Int J Mol Epidemiol Genet 4: 183-192.
10. Esparza-Lopez J, Montiel JL, Vilchis-Landeros MM, Okadome T, Miyazono K, Lopez-Casillas F, (2001). Ligand binding and functional properties of betaglycan, a co-receptor of the transforming growth factor-beta superfamily. Specialized binding regions for transforming growth factor-beta and inhibin A. J Biol Chem 276: 14588-14596.
11. Ezquerro IJ, Lasarte JJ, Dotor J, Castilla-Cortazar I, Bustos M, Penuelas I, et al. (2003). A synthetic peptide from transforming growth factor beta type III receptor inhibits liver fibrogenesis in rats with carbon tetrachloride liver injury. Cytokine 22: 12-20.
12. Gatza CE, Oh SY, Blobe GC, (2010). Roles for the type III TGF-beta receptor in human cancer. Cell Signal 22: 1163-1174.
13. He H, Liu X, Lv L, Liang H, Leng B, Zhao D, et al. (2014). Calcineurin suppresses AMPK-dependent cytoprotective autophagy in cardiomyocytes under oxidative stress. Cell Death Dis 5: e997.
14. Hermida N, Lopez B, Gonzalez A, Dotor J, Lasarte JJ, Sarobe P, et al. (2009). A synthetic peptide from transforming growth factor-beta1 type III receptor prevents myocardial fibrosis in spontaneously hypertensive rats. Cardiovasc Res 81: 601-609.
15. Hermida N, Markl A, Hamelet J, Van Assche T, Vanderper A, Herijgers P, et al. (2013). HMGCoA reductase inhibition reverses myocardial fibrosis and diastolic dysfunction through AMP-activated protein kinase activation in a mouse model of metabolic syndrome. Cardiovasc Res 99: 44-54.
16. Hu LA, Chen W, Martin NP, Whalen EJ, Premont RT, Lefkowitz RJ, (2003). GIPC interacts with the beta1-adrenergic receptor and regulates beta1-adrenergic receptor-mediated ERK activation. J Biol Chem 278: 26295-26301.
17. Hung KY, Chen CT, Huang JW, Lee PH, Tsai TJ, Hsieh BS, (2001a). Dipyridamole inhibits TGF-beta-induced collagen gene expression in human peritoneal mesothelial cells. Kidney Int 60: 1249-1257.
18. Hung KY, Chen CT, Yen CJ, Lee PH, Tsai TJ, Hsieh BS, (2001b). Dipyridamole inhibits PDGF-stimulated human peritoneal mesothelial cell proliferation. Kidney Int 60: 872-881.
19. Jang YH, Shin HS, Sun Choi H, Ryu ES, Jin Kim M, Ki Min S, et al. (2013). Effects of dexamethasone on the TGF-beta1-induced epithelial-to-mesenchymal transition in human peritoneal mesothelial cells. Lab Invest 93: 194-206.
20. Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG, (2010). Animal research: Reporting in vivo experiments: the ARRIVE guidelines. Br J Pharmacol 160: 1577-1579.
21. Kong P, Christia P, Frangogiannis NG, (2014). The pathogenesis of cardiac fibrosis. Cell Mol Life Sci 71: 549-574.
22. Kong SS, Liu JJ, Yu XJ, Lu Y, Zang WJ, (2012). Protection against ischemia-induced oxidative stress conferred by vagal stimulation in the rat heart: involvement of the AMPK-PKC pathway. Int J Mol Sci 13: 14311-14325.
23. Krzeminski TF, Nozynski JK, Grzyb J, Porc M, (2008). Wide-spread myocardial remodeling after acute myocardial infarction in rat. Features for heart failure progression. Vascul Pharmacol 48: 100-108.
24. Lagares D, Garcia-Fernandez RA, Jimenez CL, Magan-Marchal N, Busnadiego O, Lamas S, et al. (2010). Endothelin 1 contributes to the effect of transforming growth factor beta1 on wound repair and skin fibrosis. Arthritis Rheum 62: 878-889.
25. Lee JD, Hempel N, Lee NY, Blobe GC, (2010). The type III TGF-beta receptor suppresses breast cancer progression through GIPC-mediated inhibition of TGF-beta signaling. Carcinogenesis 31: 175-183.
26. Letamendia A, Lastres P, Botella LM, Raab U, Langa C, Velasco B, et al. (1998). Role of endoglin in cellular responses to transforming growth factor-beta. A comparative study with betaglycan. J Biol Chem 273: 33011-33019.
27. Li C, Qu X, Xu W, Qu N, Mei L, Liu Y, et al. (2013). Arsenic trioxide induces cardiac fibroblast apoptosis in vitro and in vivo by up-regulating TGF-beta1 expression. Toxicol Lett 219: 223-230.
28. Liang H, Zhang C, Ban T, Liu Y, Mei L, Piao X, et al. (2012). A novel reciprocal loop between microRNA-21 and TGFbetaRIII is involved in cardiac fibrosis. Int J Biochem Cell Biol 44: 2152-2160.
29. McGrath J, Drummond G, McLachlan E, Kilkenny C, Wainwright C, (2010). Guidelines for reporting experiments involving animals: the ARRIVE guidelines. Br J Pharmacol 160: 1573-1576.
30. McMurray JJ, Kjekshus J, Gullestad L, Dunselman P, Hjalmarson A, Wedel H, et al. (2009). Effects of statin therapy according to plasma high-sensitivity C-reactive protein concentration in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): a retrospective analysis. Circulation 120: 2188-2196.
31. Nemoto S, Taguchi K, Matsumoto T, Kamata K, Kobayashi T, (2012). Pravastatin normalizes ET-1-induced contraction in the aorta of type 2 diabetic OLETF rats by suppressing the KSR1/ERK complex. Am J Physiol Heart Circ Physiol 303: H893-H902.
32. Olyaei A, Greer E, Delos Santos R, Rueda J, (2011). The efficacy and safety of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors in chronic kidney disease, dialysis, and transplant patients. Clin J Am Soc Nephrol 6: 664-678.
33. Pan Z, Sun X, Shan H, Wang N, Wang J, Ren J, et al. (2012). MicroRNA-101 inhibited postinfarct cardiac fibrosis and improved left ventricular compliance via the FBJ osteosarcoma oncogene/transforming growth factor-beta1 pathway. Circulation 126: 840-850.
34. Patel R, Nagueh SF, Tsybouleva N, Abdellatif M, Lutucuta S, Kopelen HA, et al. (2001). Simvastatin induces regression of cardiac hypertrophy and fibrosis and improves cardiac function in a transgenic rabbit model of human hypertrophic cardiomyopathy. Circulation 104: 317-324.
35. Pawson AJ, Sharman JL, Benson HE, Faccenda E, Alexander SP, Buneman OP, et al.; NC-IUPHAR. (2014). The IUPHAR/BPS Guide to PHARMACOLOGY: an expert-driven knowledge base of drug targets and their ligands. Nucl Acids Res 42 (Database Issue): D1098-D1106.
36. Ponticos M, Holmes AM, Shi-wen X, Leoni P, Khan K, Rajkumar VS, et al. (2009). Pivotal role of connective tissue growth factor in lung fibrosis: MAPK-dependent transcriptional activation of type I collagen. Arthritis Rheum 60: 2142-2155.
37. Qi XF, Zheng L, Lee KJ, Kim DH, Kim CS, Cai DQ, et al. (2013). HMG-CoA reductase inhibitors induce apoptosis of lymphoma cells by promoting ROS generation and regulating Akt, Erk and p38 signals via suppression of mevalonate pathway. Cell Death Dis 4: e518.
38. Sanchez CA, Rodriguez E, Varela E, Zapata E, Paez A, Masso FA, et al. (2008). Statin-induced inhibition of MCF-7 breast cancer cell proliferation is related to cell cycle arrest and apoptotic and necrotic cell death mediated by an enhanced oxidative stress. Cancer Invest 26: 698-707.
39. Sanchez NS, Hill CR, Love JD, Soslow JH, Craig E, Austin AF, et al. (2011). The cytoplasmic domain of TGFbetaR3 through its interaction with the scaffolding protein, GIPC, directs epicardial cell behavior. Dev Biol 358: 331-343.
40. Shiroshita-Takeshita A, Brundel BJ, Burstein B, Leung TK, Mitamura H, Ogawa S, et al. (2007). Effects of simvastatin on the development of the atrial fibrillation substrate in dogs with congestive heart failure. Cardiovasc Res 74: 75-84.
41. Shyu KG, Wang BW, Chen WJ, Kuan P, Hung CR, (2010). Mechanism of the inhibitory effect of atorvastatin on endoglin expression induced by transforming growth factor-beta1 in cultured cardiac fibroblasts. Eur J Heart Fail 12: 219-226.
42. Sun YB, Qu X, Li X, Nikolic-Paterson DJ, Li J, (2013). Endothelial dysfunction exacerbates renal interstitial fibrosis through enhancing fibroblast Smad3 linker phosphorylation in the mouse obstructed kidney. PLoS ONE 8: e84063.
43. Takeda N, Kondo M, Ito S, Ito Y, Shimokata K, Kume H, (2006). Role of RhoA inactivation in reduced cell proliferation of human airway smooth muscle by simvastatin. Am J Respir Cell Mol Biol 35: 722-729.
44. Townsend TA, Robinson JY, How T, DeLaughter DM, Blobe GC, Barnett JV, (2012). Endocardial cell epithelial-mesenchymal transformation requires Type III TGFbeta receptor interaction with GIPC. Cell Signal 24: 247-256.
45. Wang Z, Wu Y, Wang H, Zhang Y, Mei L, Fang X, et al. (2014). Interplay of mevalonate and Hippo pathways regulates RHAMM transcription via YAP to modulate breast cancer cell motility. Proc Natl Acad Sci U S A 111: E89-E98.
46. Wu W, Muchir A, Shan J, Bonne G, Worman HJ, (2011). Mitogen-activated protein kinase inhibitors improve heart function and prevent fibrosis in cardiomyopathy caused by mutation in lamin A/C gene. Circulation 123: 53-61.
47. Yamashita M, Otsuka F, Mukai T, Otani H, Inagaki K, Miyoshi T, et al. (2008). Simvastatin antagonizes tumor necrosis factor-alpha inhibition of bone morphogenetic proteins-2-induced osteoblast differentiation by regulating Smad signaling and Ras/Rho-mitogen-activated protein kinase pathway. J Endocrinol 196: 601-613.
48. Yang L, Besschetnova TY, Brooks CR, Shah JV, Bonventre JV, (2010). Epithelial cell cycle arrest in G2/M mediates kidney fibrosis after injury. Nat Med 16: 535-543, 531p following 143.
49. You HJ, Bruinsma MW, How T, Ostrander JH, Blobe GC, (2007). The type III TGF-beta receptor signals through both Smad3 and the p38 MAP kinase pathways to contribute to inhibition of cell proliferation. Carcinogenesis 28: 2491-2500.